EXEL: מכפיל מחיר להכנסות Exelixis Inc

Steady demand for Cabometyx generates a reliable cash flow, supporting the historical P/S ratio for Exelixis, Inc. (EXEL). The 6.90 metric confirms the current valuation level. Financial independence from debt is based on revenues from the flagship drug, while the integration of ESG standards ensures the ethics of research and the environmental safety of drug production.

The ratio of market capitalization to annual sales determines the value of each dollar of revenue, allowing for an assessment of whether market pricing is fair under tight monetary policy. For Exelixis, Inc. (EXEL), which depends on a single drug, the revenue multiple trend serves as an indicator of investor sensitivity to patent risks and clinical trial results, helping to distinguish fundamental undervaluation from business stagnation.